Netherlands-based firm Polyganics has received funding from the European Fund for Regional Development (ERDF) by the European Union (EU) for further development of its dura sealant patch.

Made using the firm’s bioresorbable polymers, the sealant patch is being developed as a suitable dressing to reseal the outer membrane (dura) surrounding the brain.

The patch is intended to decrease leakage of cerebrospinal fluid (CSF) following brain surgery and is designed to stimulate tissue regeneration.

After the membrane has healed, the device undergoes natural and safe degradation within the body.

The firm intends to use the €1.2m grant to support clinical validation of the patch and plans to launch clinical trials early next year to evaluate safety and performance in humans.

“The firm intends to use the €1.2m grant to support clinical validation of the patch and plans to launch clinical trials early next year to evaluate safety and performance in humans.”

In partnership with the Brain Technology Institute (BTI) and Syncom, Polyganics has successfully completed studies of the sealant patch in animals.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Polyganics CEO Rudy Mareel said: “We are hugely appreciative to the EU, as well as the city and province of Groningen for their support in progressing the device into the next phase of its development.

“The grant is a great recognition of the potential of this application of our synthetic polymers, and we are pleased to have benefited from the skills and expertise of both the BTI and Syncom in its development.

“The work has important implications for improved recovery following brain surgery, including helping to prevent potentially fatal complications such as meningitis.”